5-APB-NBOMe

5-APB-NBOMe
Clinical data
Other names5APB-NBOMe; N-MOB-5-APB; N-(2-Methoxybenzyl)-5-(2-aminopropyl)benzofuran
ATC code
  • None
Identifiers
  • 1-(1-benzofuran-5-yl)-N-[(2-methoxyphenyl)methyl]propan-2-amine
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H21NO2
Molar mass295.382 g·mol−1
3D model (JSmol)
  • CC(CC1=CC2=C(C=C1)OC=C2)NCC3=CC=CC=C3OC
  • InChI=1S/C19H21NO2/c1-14(20-13-17-5-3-4-6-18(17)21-2)11-15-7-8-19-16(12-15)9-10-22-19/h3-10,12,14,20H,11,13H2,1-2H3
  • Key:NSWWDACHSBMHLV-UHFFFAOYSA-N

5-APB-NBOMe, also known as N-(2-methoxybenzyl)-5-(2-aminopropyl)benzofuran, is a drug of the phenethylamine, amphetamine, benzofuran, and 25-NB (NBOMe) families related to the entactogen and mildly psychedelic drug 5-APB.[1][2][3] It is the N-(2-methoxybenzyl) derivative of 5-APB.[4][5][3] The preclinical pharmacokinetics of 5-APB-NBOMe have been studied.[4] The drug was encountered as a novel designer drug in Germany in 2014.[2][6][4][5]

See also

References

  1. ^ Catalani V, Corkery JM, Guirguis A, Napoletano F, Arillotta D, Zangani C, et al. (August 2021). "Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise". European Neuropsychopharmacology. 49: 69–92. doi:10.1016/j.euroneuro.2021.03.006. PMID 33857740.
  2. ^ a b Potts AJ, Thomas SH, Hill SL (2022). "Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens". Novel Psychoactive Substances. Elsevier. pp. 279–300. doi:10.1016/b978-0-12-818788-3.00008-5. ISBN 978-0-12-818788-3. Retrieved 8 January 2026. The newest 25X-NBOMes to be identified include 3,4-dimethoxyamphetamine (3,4-DMA)- NBOMe [34,46], 4-methylmethamphetamine (4-MMA)-NBOMe [34,46], N‐(ortho‐methoxybenzyl)‐4‐ethylamphetamine (4‐EA‐NBOMe) [34,46] and N‐(ortho‐methoxybenzyl)‐5‐(2‐aminopropyl)benzofuran (5‐APB‐NBOMe) [34,46], which were identified in Germany in 2015.The relatively novel compounds 25H—NBOMe, 25D-NBOMe and 25E-NBOMe were identified in Japan in 2016 [47].
  3. ^ a b Richter LH, Menges J, Wagmann L, Brandt SD, Stratford A, Westphal F, et al. (2020). "In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry". Forensic Toxicology. 38 (1): 141–159. doi:10.1007/s11419-019-00498-7. ISSN 1860-8965. Retrieved 8 January 2026.
  4. ^ a b c Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis. 8 (9): 910–919. doi:10.1002/dta.1889. PMID 26606897.
  5. ^ a b Liu C, Jia W, Qian Z, Li T, Hua Z (February 2017). "Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe". Drug Testing and Analysis. 9 (2): 199–207. doi:10.1002/dta.1955. PMID 26856255.
  6. ^ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision". European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2005/387/JHA.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.